Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib monotherapy maintenance for recurrent or metastatic endometrial carcinoma
ChiCTR2000033066Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of niraparib in endometrial cancer (EC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: median progression-free survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2000033066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033066.